DRIVE is consortium consisting of three other EU partners. Each partner is funded by their national subsidy point. DRIVE makes use of virus-like particles (VLP) evolution to develop vaccine candidates to dengue virus, which is a global problem. Since vaccines are the most cost-effective way to prevent infection, but vaccines may predispose for more severe dengue, this consortium aims at developing novel vaccines. The immunogenicity, safety, and efficacy will be studied by Artemis Bio-Support using state-of-the-art assays to measure several arms of the immune response. All the immunogenicity data will be analyzed in an integrated way using bioinformatics (systems vaccinology) and machine learning tools. These tools will be developed by a partner with the consortium (Biomax).